Published in MAbs on August 17, 2016
The binding of sodium dodecyl sulphate to various proteins. Biochem J (1968) 3.51
The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol (1975) 3.31
The origin of allometric scaling laws in biology from genomes to ecosystems: towards a quantitative unifying theory of biological structure and organization. J Exp Biol (2005) 3.30
Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol (2009) 3.05
Further characterization of specific drug binding sites on human serum albumin. Mol Pharmacol (1976) 2.95
Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res (1990) 2.61
Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med (2000) 2.61
Stability engineering of antibody single-chain Fv fragments. J Mol Biol (2001) 2.58
An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng (1993) 2.31
Dual targeting strategies with bispecific antibodies. MAbs (2012) 2.13
Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol (1999) 2.02
Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull (2002) 2.02
Target-mediated drug disposition and dynamics. Biochem Pharmacol (2006) 1.85
PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev (2002) 1.84
PEGylation of therapeutic proteins. Biotechnol J (2010) 1.80
Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem (2002) 1.76
Impact of albumin on drug delivery--new applications on the horizon. J Control Release (2011) 1.72
Elastin-like polypeptides: biomedical applications of tunable biopolymers. Biopolymers (2010) 1.68
Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs (2011) 1.66
The role of CD40 in CD40L- and antibody-mediated platelet activation. Thromb Haemost (2005) 1.62
Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res (2007) 1.59
Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol (2011) 1.58
Albumin binding to FcRn: distinct from the FcRn-IgG interaction. Biochemistry (2006) 1.57
Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther (2012) 1.53
The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties. J Biol Chem (1999) 1.48
A broad range of Fab stabilities within a host of therapeutic IgGs. Biochem Biophys Res Commun (2007) 1.46
Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med (2012) 1.44
Antibody fragments: hope and hype. MAbs (2010) 1.42
Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q J Nucl Med (1998) 1.41
Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem (2007) 1.36
A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc Natl Acad Sci U S A (1993) 1.35
A modular IgG-scFv bispecific antibody topology. Protein Eng Des Sel (2009) 1.29
Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J Biol Chem (2010) 1.27
Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul Toxicol Pharmacol (2009) 1.24
Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol Cancer Ther (2008) 1.24
Albumin as a versatile platform for drug half-life extension. Biochim Biophys Acta (2013) 1.23
Plasma and tissue protein binding of drugs in pharmacokinetics. Drug Metab Rev (1976) 1.22
The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Eng Des Sel (2006) 1.20
Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs (2009) 1.17
Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel (2008) 1.17
Insulin detemir: from concept to clinical experience. Expert Opin Pharmacother (2006) 1.16
Mobility of sodium dodecyl sulphate - protein complexes. Biochem J (1976) 1.15
Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J Immunol (2010) 1.13
Interhelical hydrogen bonds in the CFTR membrane domain. Nat Struct Biol (2001) 1.12
The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein. Protein Eng Des Sel (2010) 1.06
Binding of transition metal ions to albumin: sites, affinities and rates. Biochim Biophys Acta (2013) 1.05
Removal of the conserved disulfide bridges from the scFv fragment of an antibody: effects on folding kinetics and aggregation. J Mol Biol (1999) 0.99
Prolonged in vivo residence times of antibody fragments associated with albumin. Bioconjug Chem (2001) 0.99
Thermodynamic features of the thermal unfolding of human serum albumin. Int J Biol Macromol (1997) 0.98
PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins. Protein Eng Des Sel (2013) 0.97
New strategy for the extension of the serum half-life of antibody fragments. Bioconjug Chem (2009) 0.93
Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains. J Biol Chem (2011) 0.93
Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn (2014) 0.93
Antibody generation through B cell panning on antigen followed by in situ culture and direct RT-PCR on cells harvested en masse from antigen-positive wells. J Immunol Methods (2006) 0.92
Stabilisation of the Fc fragment of human IgG1 by engineered intradomain disulfide bonds. PLoS One (2012) 0.90
Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics. J Biol Chem (2013) 0.88
Albumin and its application in drug delivery. Expert Opin Drug Deliv (2014) 0.88
A CHO cell line engineered to express XBP1 and ERO1-Lα has increased levels of transient protein expression. Biotechnol Prog (2013) 0.88
Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding. J Biol Chem (2014) 0.87
Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol. BioDrugs (2014) 0.86
Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins. Protein Eng Des Sel (2010) 0.86
A multiple-dose toxicity study of tanezumab in cynomolgus monkeys. Regul Toxicol Pharmacol (2010) 0.85
The production, characterisation and enhanced pharmacokinetics of scFv-albumin fusions expressed in Saccharomyces cerevisiae. Protein Expr Purif (2010) 0.85
Structural and thermodynamic approach to peptide immunogenicity. PLoS Comput Biol (2008) 0.84
The role of molecular imaging in diagnosis of deep vein thrombosis. Am J Nucl Med Mol Imaging (2014) 0.84
Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics. Front Immunol (2015) 0.84
Thermodynamic aspects of the thermal stability of human serum albumin. Biochem Mol Biol Int (1995) 0.83
Relevant shaking stress conditions for antibody preformulation development. Eur J Pharm Biopharm (2009) 0.83
CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study. Arthritis Res Ther (2015) 0.83
Immunogenicity assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine. Bioanalysis (2013) 0.82
Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: relevance for human safety. Toxicol Appl Pharmacol (2014) 0.80
Impact of antibody framework residue VH-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzyme. Br J Cancer (2004) 0.80
Interaction with both domain I and III of albumin is required for optimal pH-dependent binding to the neonatal Fc receptor (FcRn). J Biol Chem (2014) 0.80
Fusions of elastin-like polypeptides to pharmaceutical proteins. Methods Enzymol (2012) 0.80
GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans--PK/PD and safety. Clin Pharmacol Ther (2014) 0.78
A fully automated primary screening system for the discovery of therapeutic antibodies directly from B cells. J Biomol Screen (2014) 0.77
Current perspectives on ranibizumab. Clin Ophthalmol (2015) 0.76
Advances in medical revascularisation treatments in acute ischemic stroke. Thrombosis (2014) 0.76
Effects of PEGylated scFv antibodies against Plasmodium vivax duffy binding protein on the biological activity and stability in vitro. J Microbiol Biotechnol (2007) 0.76
Extending the serum half-life of G-CSF via fusion with the domain III of human serum albumin. Biomed Res Int (2013) 0.76
Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods (2009) 1.23
Modelling seagrass growth and development to evaluate transplanting strategies for restoration. Ann Bot (2011) 0.94